Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human and Mouse Total NFκB2 p100/p52 Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total NFκB2 p100/p52 assay is a sandwich immunoassay for quantitative detection of total NFκB2 p100/p52 in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

The AlphaLISA™ SureFire® Ultra™ Human and Mouse Total NFκB2 p100/p52 assay is a sandwich immunoassay for quantitative detection of total NFκB2 p100/p52 in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 100 Assay Points
Part #:
ALSU-TNFKB2-A-HV
List Price
USD 694.00
Unit Size: 500 Assay Points
Part #:
ALSU-TNFKB2-A500
List Price
USD 2,346.00
Unit Size: 10,000 Assay Points
Part #:
ALSU-TNFKB2-A10K
List Price
USD 14,270.00
Unit Size: 50,000 Assay Points
Part #:
ALSU-TNFKB2-A50K
List Price
USD 46,060.00

Overview

NF-κ-B2 p100 is a precursor protein of the NF-κ-B family, which plays a key role in regulating immune response, inflammation, and cell survival. p100 can be processed to p52, a transcriptionally active form that enters the nucleus to activate target genes involved in immune response and apoptosis. Dysregulation of NF-κ-B2 is associated with inflammatory diseases, autoimmune diseases, certain lymphomas and multiple myeloma, making it a potential target for therapeutic strategies.

The AlphaLISA SureFire Ultra Human and Mouse Total NFκB p100/p52 Detection Kit is a sandwich immunoassay for the quantitative detection of total NFκB p100/p52 in cellular lysates, using Alpha Technology.

Formats:

  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

 

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

 

Alpha SureFire Ultra kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening

 

Specifications

Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Host Species
Human
Mouse
Shipping Conditions
Shipped in Blue Ice
Target
NFkB2
Therapeutic Area
Inflammation
Unit Size
500 Assay Points

How it works

Total-AlphaLISA SureFire Ultra assay principle

The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.

The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure™ tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.

Assay Principle Total AlphaLISA SureFire Ultra

 

Total-AlphaLISA SureFire Ultra two-plate assay protocol

The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells' viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.

2plates-assay-protocol-AlphaLISA-Surefire-Ultra.jpg
Total-AlphaLISA SureFire Ultra one-plate assay protocol

Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.

1 plate assay protocol AlphaLISA Surefire Ultra

Assay validation

Activation of Total NFκB2 p100/p52 in TNFα treated cells

HeLa cells were seeded in a 96-well culture-treated plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of TNFα for 18 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). NFκB2 p100/p52 Total and NFκB p65 Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, TNFα triggered a dose-dependent increase in the levels of Total NFκB2 p100/p52 while Total NFκB p65 levels remained unchanged.

 

Pharmacological Validation (activator) of NFκB2 p100/p52 Total
Validation of Total NFκB2 p100/p52 in LIGHT treated cells

RT4 cells were seeded in a 96-well culture-treated plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with increasing concentrations of LIGHT for 24 hours.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). NFκB2 p100 Total, NFκB2 p100/p52 Total, and TRAF3 Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, LIGHT, a NFκB non-canonical pathway activator, triggered a dose-dependent decrease in the levels of Total TRAF3 which led to a decrease in Total NFκB2 p100 and Total NFκB2 p100/p52.

Pharmacological Validation (inhibitor) of NFκB2 p100/p52 Total
Validation of Total NFκB2 p100/p52 in LIGHT treated cells

The ratio of Total NFκB2 p100 to Total NFκB2 p100/p52 following treatment with 400 ng/mL of LIGHT for 24 hours is indicated.

As expected, LIGHT increased processing of Total p100 into Total p52, leading to a decrease in the levels of Total p100, which is demonstrated by the lower ratio observed in LIGHT treated RT4 cells.

Pharmacological Validation (inhibitor) of NFκB2 p100/p52 Total

Assay specificity/selectivity

Specificity of Total NFκB2 p100/p52 assay

Total NFκB2 p100/p52 protein levels were assessed in HCT 116 wild type (WT) and HCT 116 NFκB2 p100 knockout (KO) (Abcam ab266883) cells. Both WT and KO cells were seeded in a 96-well plate (40,000 cells/well) and incubated overnight at 37°C, 5% CO2.

After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). NFκB2 p100/p52 Total levels were then evaluated by AlphaLISA SureFire Ultra. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

As expected, Total NFκB2 p100/p52 was only detected in the WT HCT 116 cells but not in the HCT 116 NFκB2 p100 KO cell line, demonstrating assay specificity.

Specificity validation of NFκB2 p100/p52 Total

Assay versatility

Differential expression of NFκB2 p100/p52 Total assay in various cell lines

Various human and mouse adherent cells were seeded at 40,000 cells/well in a 96-well culture plate in complete medium and incubated overnight at 37°C, 5% CO2. The cells were lysed the following day with 100 µL of Lysis Buffer.

NFκB2 p100/p52 Total levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL (approximately 4,000 cells) of cell lysate were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.

Total NFκB2 p100/p52 expression was detected across all human and mouse adherent cell lines tested. A very high level of expression was detected in SW 1573 and NIH/3T3 cells, with lower levels of expression across HEK293T, A431, HeLa, RAW 264.7, SH-SY5Y and HEK293 cells, demonstrating Total NFκB2 p100/p52 assay versatility.

Versatility of NFκB2 p100/p52 Total assay in various cell lines

Resources

Are you looking for resources, click on the resource type to explore further.

SDS, COAs, Manuals and more

Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.

Technical data sheet
+ Show more
Scroll Icon